Algernon Pharmaceuticals Stock News

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF), a clinical stage Canadian pharmaceutical development company, has announced additional positive results from its phase 2a study of NP-120 (Ifenpro

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has shared positive topline data showing it has met the co-primary endpoint in the Phase 2 proof of concept study evaluating its repurposed drug

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF), a clinical stage Canadian pharmaceutical development company, has provided an update on its chronic kidney disease (CKD) research program with NP-

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has provided an update on its planned phase 1 clinical human study of AP-188 (dimethyltryptamine or DMT), a hallucinogenic tryptamine drug, for use

Algernon Pharmaceuticals Inc said that it had included nicotinate and pamoate as novel salt forms of DMT as part of its intellectual property patent applications filed in early 2021. Nicotinate and pa

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) revealed that it has awarded a contract to China's Zhejiang Ausun Pharmaceutical Company Limited to begin the manufacturing of a cGMP supply of its

Algernon Pharmaceuticals Inc said it has completed enrollment in a Phase 2 study for its repurposed drug NP-120 (Ifenprodil) aimed at idiopathic pulmonary fibrosis (IPF), a chronic, progressive lung d

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF), the drug repurposing group, said the Canadian patent office approved its application for a claim involving its drug Ifenprodil for treating idiopa

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) told investors that it believes the company has "maximized" its intellectual property (IP) position around DMT for stroke because it included so-ca

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has received positive feedback from the US Food and Drug Administration at its pre-Investigational New Drug (pre-IND) meeting for its inve

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) told investors it now has potentially enough clinical-grade supply of its DMT psychedelic compound to complete its planned Phase 1 and Phase 2 clin

Algernon Pharmaceuticals Inc said it has added a clinical trial site in Australia for its ongoing Phase 2 NP-120 (Ifenprodil) idiopathic pulmonary fibrosis (IPF) and chronic cough study.  Correspondi

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has appointed James Kinley as its chief financial officer, effective December 1, 2021. Kinley will report to CEO Christopher Moreau, according to a

(PR-inside.com) VANCOUVER, BC / ACCESSWIRE / November 24, 2021 / The Power Play by The Market Herald releases new interviews with Algernon Pharmaceuticals, Better Plant Sciences and Mednow Inc. discussing their latest news. The Power Play by The Market Herald provides investors with a quick snapshot of what they need to know about the company''s latest press release through exclusive insights and interviews with company executives. Algernon Pharmaceuticals (CSE:AGN) receives positive feedback from the U.S. FDA for Phase 1 Ifenprodil small cell lung cancer studyAlgernon Pharmaceuticals (AGN) has received positive feedback from the U.S. FDA for its investigation of NP-120 (Ifenprodil) to treat ..

VANCOUVER, British Columbia, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the Company or Algernon) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) a clinical stage pharmaceutical development company, is pleased to announce that it has received positive feedback from the U.S. Food and Drug Administration (U.S. FDA) at its pre-IND (Investigational New Drug) meeting for its investigation of NP-120 (Ifenprodil) for the treatment of small cell lung cancer (SCLC). Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B).